首页> 外文学位 >A patient-perspective approach to Medicare Part D prescription drug plan costs.
【24h】

A patient-perspective approach to Medicare Part D prescription drug plan costs.

机译:从患者角度出发的Medicare D部分处方药计划费用。

获取原文
获取原文并翻译 | 示例

摘要

ince its inception in 2003, Medicare Part D has become the largest addition to the Medicare benefit since it was signed into law in 1965. Despite this novel prescription drug coverage, the design and benefit structure of Medicare Part D has been challenging for beneficiaries and healthcare providers alike. Beneficiaries have been faced with a plethora of drug plan offerings. Additionally, the unique benefit structure and annual variation in plan offerings and plan parameters have left beneficiaries unaware of gaps in coverage and reluctant to re-evaluate plan offerings. Despite these issues, to date the total out-of-pocket costs for beneficiaries enrolled in Medicare Part D have not been examined. To mitigate this void, three studies were conducted to determine trends in the total out-of-pocket costs incurred by Medicare beneficiaries enrolled in Medicare Part D prescription drug plans. Pharmacy claims data of 50 randomly sampled patients from a database of Medicare-eligible individuals were used to generate medication profiles. To maintain a patient-perspective approach, these profiles were then entered into the Plan Finder Tool on the Medicare website in order to determine the estimated annual costs for each stand-alone prescription drug plan in each Medicare region. It was determined that Medicare Part D plan costs increased from 2007 to 2008 in most regions, however in 13 of 34 regions patients may not have paid more if they were enrolled in the lowest cost plan each year. Based on these findings, the opportunity cost of neglecting to re-evaluate prescription drug plan offerings for 2008 was examined. A significant increase ranging from
机译:自2003年成立以来,Medicare D部分已成为自1965年签署法律以来对Medicare福利的最大补充。尽管有了新颖的处方药覆盖范围,Medicare D部分的设计和利益结构一直对受益人和医疗保健构成挑战提供者都一样。受益人面临着过多的毒品计划产品。此外,独特的福利结构以及计划产品和计划参数的年度变化,使受益人没有意识到承保范围的不足,也不愿重新评估计划产品。尽管存在这些问题,但迄今为止,尚未对参加Medicare D部分的受益人的自付费用总额进行检查。为了减轻这种空缺,进行了三项研究,以确定参加Medicare D部分处方药计划的Medicare受益人自付费用的总费用趋势。从符合Medicare资格的个人数据库中随机抽取50名患者的药房索赔数据用于生成药物资料。为了维持患者的观点,然后将这些配置文件输入到Medicare网站上的“计划查找器”工具中,以确定每个Medicare地区每个独立处方药计划的估计年度费用。已确定大多数地区的Medicare Part D计划费用从2007年到2008年有所增加,但是,如果34个地区中的13个地区的患者每年参加最低费用计划,则可能未支付更多费用。基于这些发现,研究了忽视重新评估2008年处方药计划产品的机会成本。显着增加

著录项

  • 作者

    Walberg, Mark P.;

  • 作者单位

    University of the Pacific.;

  • 授予单位 University of the Pacific.;
  • 学科 Gerontology.;Health Sciences Pharmacy.;Health Sciences Health Care Management.
  • 学位 Ph.D.
  • 年度 2009
  • 页码 73 p.
  • 总页数 73
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 老年病学;预防医学、卫生学;药剂学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号